Image

Breaking News

Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma”
09/30/2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Blog - Melanoma360
, 
Breaking News
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Blog - Melanoma360
, 
Breaking News
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Blog - Melanoma360
, 
Breaking News
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Blog - Melanoma360
, 
Breaking News
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Blog - Melanoma360
, 
Breaking News
Featured image for “Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag”
07/22/2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
Blog - Melanoma360
, 
Breaking News
Featured image for “Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma”
06/06/2022

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

(reprint from Biospace, published: Jun 03, 2022) Immunocore announcesclinical trial collaboration with Sanofito evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2,in combination with KIMMTRAK® in patients with metastatic cutaneous…
Blog - Melanoma360
, 
Breaking News
Featured image for “Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma”
06/05/2022

Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma

(reprint from Targeted Oncology, published: Jun 05, 2022) Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II…
Blog - Melanoma360
, 
Breaking News
Featured image for “FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
03/19/2022

FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
Blog - Melanoma360
, 
Breaking News
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/30/2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Featured image for “Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma”
Blog - Melanoma360
 | 
Breaking News
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
Blog - Melanoma360
 | 
Breaking News
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
Blog - Melanoma360
 | 
Breaking News
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
Blog - Melanoma360
 | 
Breaking News
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
Blog - Melanoma360
 | 
Breaking News
07/22/2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
Featured image for “Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag”
Blog - Melanoma360
 | 
Breaking News
06/06/2022

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

(reprint from Biospace, published: Jun 03, 2022) Immunocore announcesclinical trial collaboration with Sanofito evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2,in combination with KIMMTRAK® in patients with metastatic cutaneous…
Featured image for “Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma”
Blog - Melanoma360
 | 
Breaking News
06/05/2022

Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma

(reprint from Targeted Oncology, published: Jun 05, 2022) Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II…
Featured image for “Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma”
Blog - Melanoma360
 | 
Breaking News
03/19/2022

FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
Featured image for “FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News

Recent Posts

Featured image for “Restful Recovery: Navigating Sleep and Cancer with Dr. Daniel Barone”
Sep. 11, 2024

Restful Recovery: Navigating Sleep and Cancer with Dr. Daniel Barone

Featured image for “Ways to Give: What Is Payroll Giving?”
Sep. 01, 2024

Ways to Give: What Is Payroll Giving?

Featured image for “Side Effect Central – Colitis”
Aug. 26, 2024

Side Effect Central – Colitis

Featured image for “New Specialty Manages Skin Concerns and Keeps Patients on Therapy”
Aug. 26, 2024

New Specialty Manages Skin Concerns and Keeps Patients on Therapy

Featured image for “From Tanning Beds to Sun Safety: Brittanny Groover’s Journey of Melanoma Awareness and Advocacy”
Aug. 01, 2024

From Tanning Beds to Sun Safety: Brittanny Groover’s Journey of Melanoma Awareness and Advocacy

Filter by Tag